Adc Therapeutics Sa's

• ADCT's Stock Performance relative to its Competitors

89bio Inc Share Performance +85.73% One Year

89bio Inc Profile 89bio Inc operates as a biopharmaceutical company focused on developing and commercializing transformative therapies for liver and cardio-metabolic diseases. The company's business model revolves around identifying and developing potential drug candidates through its unique platform, with the aim of meeting the unmet medical needs of patients. By leveraging its expertise and scientific advancements, 89bio Inc strives to bring innovative treatments to market, improving the lives of individuals suffering from these conditions. More about 89bio Inc 's Market Share

Pyxis Oncology Inc Share Performance +238.26% This Year

Pyxis Oncology Inc Profile Pyxis Oncology Inc is a biotechnology company focused on developing innovative cancer therapies. Their business model revolves around leveraging novel insights into the immune system to develop a pipeline of potential immunotherapies for cancer treatment. Pyxis Oncology aims to collaborate with strategic partners to advance their therapies through preclinical and clinical development, ultimately aiming to improve patient outcomes in the field of oncology. More about Pyxis Oncology Inc 's Market Share

Janux Therapeutics Inc Share Performance +12.26% Over The Past 5 Days

Janux Therapeutics Inc Profile Janux Therapeutics Inc is a biotechnology company that focuses on developing and commercializing innovative cancer treatments. Their business model revolves around leveraging their expertise in immunotherapies and bispecific antibody platforms to create novel therapies that target tumor cells and activate the patient's immune system. By partnering with pharmaceutical companies and conducting clinical trials, they aim to bring effective and personalized cancer treatments to market. More about Janux Therapeutics Inc 's Market Share

United Therapeutics Corporation Share Performance -8.51% 30 Days

United Therapeutics Corporation Profile United Therapeutics Corporation's business model revolves around the development and commercialization of innovative therapeutics for treating rare diseases and chronic conditions. They focus on researching, manufacturing, marketing, and distributing their specialized pharmaceutical and medical products to healthcare providers and patients globally. More about United Therapeutics Corporation's Market Share

Ligand Pharmaceuticals Incorporated Share Performance -4.84% 30 Days

Ligand Pharmaceuticals Incorporated Profile Ligand Pharmaceuticals Inc operates on a business model focused on discovering and acquiring new drugs and technologies to license them to pharmaceutical companies. They generate revenue through licensing fees, milestone payments, and royalties from the sales of their partnered products. Their approach allows them to leverage their expertise and resources while minimizing risk, ultimately leading to long-term value creation for their shareholders. More about Ligand Pharmaceuticals Incorporated's Market Share

Sources: Adc Therapeutics Sa’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Saturday, September 5, 2026 3:41 PM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Adc Therapeutics Sa versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.